In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly and Merck Lead the Way With Asian FIPNet Strategies

Executive Summary

There's a new acronym to learn:FIPNet--for fully integrated pharmaceutical network. Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality research available in India and China--countries that also should prove to be a major source of future customers. Merck and Eli Lilly are two companies leading the FIPNet charge.
Advertisement

Related Content

BGI Touts Eventual Merck Deal
Flexion Exploits Big Pharma as Discovery Supplier
Lilly Tries to Buy Time
New Frontiers in Pharma R&D Investment
Cliff Nearing, It's Lilly's Turn to Restructure
New Initiatives to Improve Diagnostic Data Access
Pharma's Strategic Divide: Focus or Diversify
China: The Wild, Wild East for Medical Devices
Lilly's Chorus Experiment
Lilly's Chorus Experiment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel